Recent ADM research shows close to a third of consumers have become more conscious about their weight, the company says
ADM has partnered with i-Health Inc. to formulate its Culturelle metabolism and weight management product featuring ADM’s probiotic BPL1 strain.
The Bifidobacterium animalis subsp. lactis BPL1 (CECT 8145) strain is reportedly supported by a portfolio of pre-clinical and clinical evidence demonstrating its potential metabolic health and weight management benefits.
“As this is the first Culturelle product to target metabolic health and weight management, we’re proud to say it’s formulated with BPL1 and highlight the robust science that supports it. This has been possible thanks to our strong partnership with ADM, and we’re looking forward to exploring further opportunities together,” said Eric Bianco, Brand Lead for North America at Culturelle.
“ADM invests in industry-leading microbiome research and innovation to help our partners and customers develop evidence-based solutions in a variety of applications. Together we’re supporting the metabolic health needs of consumers around the world,” said Marta Tortajada Serra, Vice President, Science & Technology at ADM.
Recent ADM research shows close to a third of consumers have become more conscious about their weight, the company says, compared to just 21% prior to the pandemic. Consumers are also more informed about how their metabolic health affects their overall health, especially their immune health and mental health, through the gut microbiome. 27% of dietary supplement users increased their usage over the last five years, with 40% citing increased concerns for their health as the reason why.